肠道微生物组作为2型糖尿病高血糖预防和治疗靶点:从当前人类证据到未来可能性
本综述旨在梳理利用可修饰的肠道微生物组开发人类高血糖和2型糖尿病预防与治疗策略的当前及未来可能性和挑战。文章讨论了2型糖尿病中人类肠道微生物组的组成与功能,总结了涉及或基于微生物组修饰的当前治疗策略(饮食、益生菌、二甲双胍和减重手术)的最新证据,并综述了未来基于肠道的降糖方法,包括个性化营养、益生菌、丙酸靶向递送、二甲双胍下消化道靶向递送、粪菌移植和基因工程菌等。
要点
- 小鼠机制研究支持肠道微生物组在代谢疾病中的因果作用,但支持因果关系的人类数据不足。
- 当前涉及微生物组修饰的治疗策略包括饮食、益生菌、二甲双胍和减重手术。
- 未来基于肠道的降糖方法包括个性化营养、益生菌、靶向递送丙酸或二甲双胍、粪菌移植和基因工程菌。
核心结论
- 肠道微生物组具有可修饰性,在人类高血糖和2型糖尿病的预防与治疗策略开发中具有当前和未来的可能性与挑战。
研究设计与样本
- 综述,覆盖利用肠道微生物组开发人类高血糖和2型糖尿病预防与治疗策略的当前及未来可能性和挑战。
主要发现
- 肠道微生物基因组约有人类基因组500倍多的基因,互补人类编码潜力。
- 微生物基因对关键代谢过程至关重要,如分解不可消化膳食纤维为短链脂肪酸、生物合成氨基酸和维生素、产生神经递质和激素。
- 过去十年积累的证据支持粪便样本分析的肠道微生物群在血糖控制和2型糖尿病中的作用。
- 小鼠机制研究支持肠道微生物群在代谢疾病中的因果作用,但支持因果关系的人类数据不足。
局限性
- 支持因果关系的人类数据不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The totality of microbial genomes in the gut exceeds the size of the human genome, having around 500-fold more genes that importantly complement our coding potential. Microbial genes are essential for key metabolic processes, such as the breakdown of indigestible dietary fibres to short-chain fatty acids, biosynthesis of amino acids and vitamins, and production of neurotransmitters and hormones. During the last decade, evidence has accumulated to support a role for gut microbiota (analysed from faecal samples) in glycaemic control and type 2 diabetes. Mechanistic studies in mice support a causal role for gut microbiota in metabolic diseases, although human data favouring causality is insufficient. As it may be challenging to sort the human evidence from the large number of animal studies in the field, there is a need to provide a review of human studies. Thus, the aim of this review is to cover the current and future possibilities and challenges of using the gut microbiota, with its capacity to be modified, in the development of preventive and treatment strategies for hyperglycaemia and type 2 diabetes in humans. We discuss what is known about the composition and functionality of human gut microbiota in type 2 diabetes and summarise recent evidence of current treatment strategies that involve, or are based on, modification of gut microbiota (diet, probiotics, metformin and bariatric surgery). We go on to review some potential future gut-based glucose-lowering approaches involving microbiota, including the development of personalised nutrition and probiotic approaches, identification of therapeutic components of probiotics, targeted delivery of propionate in the proximal colon, targeted delivery of metformin in the lower gut, faecal microbiota transplantation, and the incorporation of genetically modified bacteria that express therapeutic factors into microbiota. Finally, future avenues and challenges for understanding the interplay between human nutrition, genetics and microbial genetics, and the need for integration of human multi-omic data (such as genetics, transcriptomics, epigenetics, proteomics and metabolomics) with microbiome data (such as strain-level variation, transcriptomics, proteomics and metabolomics) to make personalised treatments a successful future reality are discussed.
引用
- Brunkwall L, Orho-Melander M. The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes: from current human evidence to future possibilities. Diabetologia. 2017. PMID: 28434033. doi:10.1007/s00125-017-4278-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。